Hepatitis C virus (HCV) infection is the most common cause of newly diagnosed chronic liver disease world wide. Prevention of HCV infection complications can be achieved by antiviral therapy based on the use of a combination of pegylated Interferon (IFN) alfa and Ribavirin.Cardiovascular complications occurred in clinical trials of interferon. The most common presentations of cardio toxicity were cardiac arrhythmias, dilated cardiomyopathy and symptoms of ischemic heart disease, including myocardial infarction and other effects less common and dangerous: low-level conduction impairment or reversible hypertension.